MKS (MKSI - Free Report) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving.
The upward trend in estimate revisions for this maker of analysis and processing equipment for semiconductor companies reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For MKS, strong agreement among the covering analysts in revising earnings estimates upward has resulted in meaningful improvement in consensus estimates for the next quarter and full year.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate RevisionsThe company is expected to earn $2.71 per share for the current quarter, which represents a year-over-year change of +53.1%.
The Zacks Consensus Estimate for MKS has increased 26.24% over the last 30 days, as three estimates have gone higher compared to no negative revisions.
Current-Year Estimate RevisionsThe company is expected to earn $11.05 per share for the full year, which represents a change of +40.2% from the prior-year number.
There has been an encouraging trend in estimate revisions for the current year as well. Over the past month, six estimates have moved up for MKS versus no negative revisions. This has pushed the consensus estimate 12.22% higher.
Favorable Zacks RankThanks to promising estimate revisions, MKS currently carries a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom LineMKS shares have added 17% over the past four weeks, suggesting that investors are betting on its impressive estimate revisions. So, you may consider adding it to your portfolio right away to benefit from its earnings growth prospects.
Did you analyze how MKS (MKSI - Free Report) fared in its international operations for the quarter ending March 2026? Given the widespread global presence of this maker of analysis and processing equipment for semiconductor companies, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities.
In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the key is to grasp how reliant a company is on overseas markets, as this provides insights into the durability of its earnings, its ability to exploit different economic cycles, and its overall growth capabilities.
Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.
While analyzing MKSI's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.
For the quarter, the company's total revenue amounted to $1.08 billion, experiencing an increase of 15.2% year over year. Next, we'll explore the breakdown of MKSI's international revenue to understand the importance of its overseas business operations.
Trends in MKSI's Revenue from International MarketsOf the total revenue, $62 million came from Taiwan during the last fiscal quarter, accounting for 5.8%. This represented a surprise of -10.07% as analysts had expected the region to contribute $68.94 million to the total revenue. In comparison, the region contributed $64 million, or 6.2%, and $60 million, or 6.4%, to total revenue in the previous and year-ago quarters, respectively.
Other International accounted for 21.3% of the company's total revenue during the quarter, translating to $230 million. Revenues from this region represented a surprise of -16.13%, with Wall Street analysts collectively expecting $274.23 million. When compared to the preceding quarter and the same quarter in the previous year, Other International contributed $276 million (26.7%) and $246 million (26.3%) to the total revenue, respectively.
China generated $252 million in revenues for the company in the last quarter, constituting 23.4% of the total. This represented a surprise of +2.22% compared to the $246.53 million projected by Wall Street analysts. Comparatively, in the previous quarter, China accounted for $257 million (24.9%), and in the year-ago quarter, it contributed $219 million (23.4%) to the total revenue.
During the quarter, Singapore contributed $73 million in revenue, making up 6.8% of the total revenue. When compared to the consensus estimate of $70.06 million, this meant a surprise of +4.2%. Looking back, Singapore contributed $70 million, or 6.8%, in the previous quarter, and $63 million, or 6.7%, in the same quarter of the previous year.
During the quarter, Japan contributed $67 million in revenue, making up 6.2% of the total revenue. When compared to the consensus estimate of $63.79 million, this meant a surprise of +5.03%. Looking back, Japan contributed $57 million, or 5.5%, in the previous quarter, and $68 million, or 7.3%, in the same quarter of the previous year.
Revenue Projections for Overseas MarketsIt is projected by analysts on Wall Street that MKS will post revenues of $1.2 billion for the ongoing fiscal quarter, an increase of 23.7% from the year-ago quarter. The expected contributions from Taiwan, Other International, China, Singapore and Japan to this revenue are 5.9%, 23.3%, 21%, 5.9%, and 5.2%, translating into $70.9 million, $279.94 million, $252.28 million, $71.47 million, and $62.06 million, respectively.
For the entire year, the company's total revenue is forecasted to be $4.73 billion, which is an improvement of 20.5% from the previous year. The revenue contributions from different regions are expected as follows: Taiwan will contribute 6.1% ($290.2 million), Other International 24.5% ($1.16 billion)China 22.1% ($1.05 billion)Singapore 6.4% ($301.2 million) and Japan 5.3% ($249.59 million) to the total revenue.
Final ThoughtsRelying on international markets for revenues, MKS faces both prospects and perils. Thus, tracking the company's international revenue trends is essential for accurately projecting its future trajectory.
In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.
At Zacks, a company's changing earnings outlook is given considerable attention due to its proven, strong influence on a stock's price performance in the near term. The connection here is straightforward and positive: when earnings estimates are revised upward, the stock price generally follows suit, increasing as well.
Our proprietary stock rating tool, the Zacks Rank, with its externally validated exceptional track record, harnesses the power of earnings estimate revisions to serve as a dependable measure for anticipating the short-term price trends of stocks.
At present, MKS holds a Zacks Rank #1 (Strong Buy). This ranking implies that its near-term performance might beat the overall market movement. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Assessing MKS' Stock Price Movement in Recent TimesThe stock has witnessed an increase of 13.7% over the past month versus the Zacks S&P 500 composite's an increase of 8.8%. In the same interval, the Zacks Computer and Technology sector, to which MKS belongs, has registered no change. Over the past three months, the company's shares saw an increase of 18.6%, while the S&P 500 increased by 7.1%. In comparison, the sector experienced no change during this timeframe.
MKSI Inc. delivered a Q1 FY2026 earnings beat, with revenue up 15% YoY and EPS up 35%, maintaining a Buy rating. Management indicated WFE spend potentially rising to $170-180 billion for 2027, positioning MKSI for significant upside as a key subsystem supplier. A new $100 million, 500,000 sq. ft. facility in Malaysia will expand capacity by June 2026, supporting long-term growth and customer alignment.
It has been about a month since the last earnings report for MKS (MKSI - Free Report) . Shares have added about 9.8% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is MKS due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for MKS Inc. before we dive into how investors and analysts have reacted as of late.
MKSI Q1 Earnings Beat Estimates, Revenue Increase Y/YMKS Inc.’s first-quarter 2026 non-GAAP earnings of $2.30 per share increased 34.5% year over year. The figure surpassed the Zacks Consensus Estimate by 15.21%.
Revenues came in at $1.08 billion, rising 15.2% from the year-ago quarter and beating the Zacks Consensus Estimate by 2.95%. Strength was supported by broad-based demand tied to AI-related investment.
Product revenues (88.5% of total revenues) totaled $954 million, up 16.5% year over year. Services revenues (11.5% of total revenues) increased 6% year over year to $124 million.
MKSI Q1 Top-Line DetailsSemiconductor end-market revenues totaled $466 million (43.2% of total revenues), increasing 13% year over year, with management citing broad-based growth across products aimed at DRAM, NAND and foundry/logic applications. The company also pointed to sequential improvement in power solutions as NAND equipment upgrades increased.
Electronics & Packaging revenues rose 27% year over year to $321 million, and contributed 29.8% of total revenue in the reported quarter. The company attributed the performance to strength in flexible PCB drilling systems supported by consumer electronics seasonality, along with solid results in chemistry and chemistry equipment.
Specialty Industrial revenues increased 8% from the prior-year period to $291 million and contributed 27% of total revenues, even as results reflected a sequential dip tied largely to Lunar New Year seasonality. The company cited year-over-year strength, driven by datacom and defense markets.
MKSI’s Q1 Operating DetailsIn the first quarter of 2026, gross margin contracted 40 basis points (bps) on a year-over-year basis to 47%.
Adjusted EBITDA increased 17.4% year over year to $277 million. Adjusted EBITDA margin expanded 50 bps year over year to 25.7%.
Non-GAAP operating expenses were $271 million, and the company flagged higher R&D investment and a seasonal lift in stock-based compensation as key contributors to spending levels.
On a non-GAAP basis, operating margin expanded 160 bps to 21.8% from 20.2% a year ago, reflecting revenue growth and operating leverage.
MKSI’s Balance SheetAs of March 31, 2026, MKS Instruments had cash and cash equivalents of $569 million compared with $675 million as of Dec. 31, 2025.
As of March 31, 2026, long-term debt totaled $2.65 billion.
Cash flow from operations was $53 million in the first quarter of 2026 compared with $142 million in the previous quarter.
The free cash flow was $29 million compared with $91 million in the first quarter of 2025.
MKS anticipates a gross margin of 47% (+/- 1%). The company expects an adjusted EBITDA of $328 million (+/- 26 million).
On a non-GAAP basis, MKSI expects earnings of $2.90 (+/- 30 cents) per share.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision.
The consensus estimate has shifted 25.39% due to these changes.
VGM ScoresAt this time, MKS has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise MKS has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry PlayerMKS is part of the Zacks Electronics - Miscellaneous Products industry. Over the past month, Teradyne (TER - Free Report) , a stock from the same industry, has gained 14.9%. The company reported its results for the quarter ended March 2026 more than a month ago.
Teradyne reported revenues of $1.28 billion in the last reported quarter, representing a year-over-year change of +87%. EPS of $2.56 for the same period compares with $0.75 a year ago.
Teradyne is expected to post earnings of $1.99 per share for the current quarter, representing a year-over-year change of +249.1%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
Teradyne has a Zacks Rank #1 (Strong Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.
Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase, investors find themselves invested in shares that have limited to no upside or even a downside. So, betting on a stock just by looking at the traditional momentum parameters could be risky at times.
It could be safer to invest in bargain stocks that have been witnessing price momentum recently. While the Zacks Momentum Style Score (part of the Zacks Style Scores system), which pays close attention to trends in a stock's price or earnings, is pretty useful in identifying great momentum stocks, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
Krispy Kreme (DNUT - Free Report) is one of the several great candidates that made it through the screen. While there are numerous reasons why this stock is a great choice, here are the most vital ones:
Investors' growing interest in a stock is reflected in its recent price increase. A price change of 20.6% over the past four weeks positions the stock of this doughnut wholesaler and retailer well in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. DNUT meets this criterion too, as the stock gained 27.9% over the past 12 weeks.
Moreover, the momentum for DNUT is fast paced, as the stock currently has a beta of 1.27. This indicates that the stock moves 27% higher than the market in either direction.
Given this price performance, it is no surprise that DNUT has a Momentum Score of A, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped DNUT earn a Zacks Rank #1 (Strong Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, DNUT is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. DNUT is currently trading at 0.46 times its sales. In other words, investors need to pay only 46 cents for each dollar of sales.
So, DNUT appears to have plenty of room to run, and that too at a fast pace.
In addition to DNUT, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
Key Takeaways OLLI's Army loyalty program grew 23% in the Q4 of fiscal 2025, with total members surpassing 17 million.Ollie's Army drives customer engagement, traffic and acquisition through exclusive perks and events.OLLI expands reach with digital marketing, broader demographics and value-driven positioning. Ollie’s Bragain Outlet Holdings, Inc. (OLLI - Free Report) is set to enhance and grow the Ollie’s Army loyalty program through several initiatives, including introducing an Ollie’s Army Night, making Ollie’s Days exclusive to members, providing advance notice of special events and launching the Ollie’s credit card. Store teams played a strong role in communicating benefits and enrolling customers, contributing to effective program expansion.
The Ollie’s Army loyalty program recorded strong growth, with new memberships increasing 23%, and the total customer file expanding by more than 12%, reaching 17 million members in fiscal 2025. Alongside this accelerated membership growth, the company is also attracting a broader and more diverse customer base, improving overall reach and engagement. As it expands from East to West, customer demographics continue to widen. The company’s strong value proposition and unmatched deals are driving increased consumer interest, with clear benefits from shoppers seeking value and trading down.
Ollie’s Army growth is contributing significantly to increased customer traffic and engagement, while also supporting stronger sales momentum. This expansion is helping the company reach a broader customer base and reinforcing OLLI’s value-driven positioning.
The Zacks Rundown for OLLIShares of OLLI have plunged 25.4% in the past six months compared with the industry’s decline of 2.8%.
Image Source: Zacks Investment Research
From a valuation standpoint, OLLI trades at a forward price-to-earnings ratio of 19.90X, higher than the industry’s average of 17.66X. OLLI currently carries a Zacks Rank #3 (Hold).
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for OLLI’s current and next fiscal year earnings implies a year-over-year rise of 16.1% and 13.5%, respectively.
Image Source: Zacks Investment Research
Stocks to ConsiderSome better-ranked stocks have been discussed below:
Krispy Kreme, Inc. (DNUT - Free Report) produces doughnuts in the United States, the United Kingdom, Ireland, Australia, New Zealand, Mexico, Canada, Japan, and internationally. At present, DNUT sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for DNUT’s current fiscal-year sales implies a decline of 10.1%, and the same for earnings implies growth of 60% from the year-ago reported figures. DNUT delivered a trailing four-quarter earnings surprise of 14.6%, on average.
ARKO Corp. (ARKO - Free Report) operates a chain of convenience stores in the United States. ARKO currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for ARKO's current fiscal-year sales implies a decline of 4.9%, while the same for current fiscal-year earnings implies growth of 73.3% from the year-ago reported figures. ARKO delivered a trailing four-quarter earnings surprise of 36.5%, on average.
B&G Foods, Inc. (BGS - Free Report) manufactures, sells, and distributes a portfolio of shelf-stable and frozen foods and household products. BGS currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for B&G Foods’ current fiscal-year earnings implies growth of 5.9% from the year-ago actuals. BGS delivered a trailing four-quarter negative earnings surprise of 19.5%, on average.
The market expects Krispy Kreme (DNUT - Free Report) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 7. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis doughnut wholesaler and retailer is expected to post quarterly loss of $0.03 per share in its upcoming report, which represents a year-over-year change of +40%.
Revenues are expected to be $355.2 million, down 5.3% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 30% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Krispy Kreme?For Krispy Kreme, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.
On the other hand, the stock currently carries a Zacks Rank of #1.
So, this combination makes it difficult to conclusively predict that Krispy Kreme will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Krispy Kreme would post earnings of $0.03 per share when it actually produced earnings of $0.09, delivering a surprise of +200.00%.
Over the last four quarters, the company has beaten consensus EPS estimates three times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Krispy Kreme doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
An Industry Player's Expected ResultsAnother stock from the Zacks Consumer Products - Staples industry, BBB Foods (TBBB - Free Report) , is soon expected to post loss of $0.19 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of -375%. Revenues for the quarter are expected to be $1.28 billion, up 52.9% from the year-ago quarter.
The consensus EPS estimate for BBB Foods has been revised 36.4% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -26.32%.
This Earnings ESP, combined with its Zacks Rank #5 (Strong Sell), makes it difficult to conclusively predict that BBB Foods will beat the consensus EPS estimate. The company could not beat consensus EPS estimates in any of the last four quarters.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
CHARLOTTE, N.C.--(BUSINESS WIRE)--Krispy Kreme, Inc. (NASDAQ: DNUT) (“Krispy Kreme”, “KKI”, or the “Company”) today reported financial results for the quarter ended March 29, 2026. First Quarter 2026 Highlights (vs Q1 2025) Net revenue of $367.0 million declined 2.2%, reflecting the strategic closure of underperforming doors completed in the third quarter of 2025 Systemwide sales of $485.3 million increased 0.7% in constant currency excluding sales attributable to the now-ended McDonald's USA p.
Krispy Kreme narrowed its loss and expanded margins in the recent quarter as turnaround efforts continued to pay off, though revenue once again declined following last year's move to exit weaker sales locations.
Krispy Kreme (DNUT - Free Report) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -87.27%. A quarter ago, it was expected that this doughnut wholesaler and retailer would post earnings of $0.03 per share when it actually produced earnings of $0.09, delivering a surprise of +200%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Krispy Kreme, which belongs to the Zacks Consumer Products - Staples industry, posted revenues of $367.03 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.33%. This compares to year-ago revenues of $375.18 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Krispy Kreme shares have lost about 8.5% since the beginning of the year versus the S&P 500's gain of 7.6%.
What's Next for Krispy Kreme?While Krispy Kreme has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Krispy Kreme was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $339.31 million in revenues for the coming quarter and $0.02 on $1.4 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Consumer Products - Staples is currently in the bottom 16% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Village Farms (VFF - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.
This greenhouse operator is expected to post quarterly earnings of $0.02 per share in its upcoming report, which represents a year-over-year change of +133.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Village Farms' revenues are expected to be $48.02 million, down 37.7% from the year-ago quarter.
Krispy Kreme (DNUT - Free Report) reported $367.03 million in revenue for the quarter ended March 2026, representing a year-over-year decline of 2.2%. EPS of -$0.05 for the same period compares to -$0.05 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $355.2 million, representing a surprise of +3.33%. The company delivered an EPS surprise of -87.27%, with the consensus EPS estimate being -$0.03.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Krispy Kreme performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Total Global Points of Access: 15,125 versus 14,912 estimated by two analysts on average.Hubs, by segment and type - U.S. - Doughnut Factories: 6 versus the two-analyst average estimate of 6.Global Points of Access, by segment and type - U.S. - Fresh Shops: 46 compared to the 69 average estimate based on two analysts.Global Points of Access, by segment and type - U.S. - DFD Doors: 5,949 versus the two-analyst average estimate of 6,823.Global Points of Access, by segment and type - U.S. - Total: 6,171 versus the two-analyst average estimate of 7,128.Global Points of Access, by segment and type - International - Hot Light Theater Shops: 47 versus 48 estimated by two analysts on average.Global Points of Access, by segment and type - International - Fresh Shops: 448 compared to the 529 average estimate based on two analysts.Global Points of Access, by segment and type - International - Carts, Food Trucks, and Other: 17 versus 18 estimated by two analysts on average.Global Points of Access, by segment and type - International - DFD Doors: 3,630 versus 4,193 estimated by two analysts on average.Geographic Revenue- U.S.: $221.55 million versus the two-analyst average estimate of $211.93 million. The reported number represents a year-over-year change of -6.3%.Geographic Revenue- Market Development: $20.23 million compared to the $20.9 million average estimate based on two analysts. The reported number represents a change of +6.4% year over year.Geographic Revenue- International: $125.26 million versus $118.48 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.7% change.View all Key Company Metrics for Krispy Kreme here>>>
Shares of Krispy Kreme have returned +10.5% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Zacks' 7 Best Strong Buy Stocks (New Research Report) Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Click Here, It's Really Free
Published in earnings earnings-estimates-revisions earnings-surprise
Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase, investors find themselves invested in shares that have limited to no upside or even a downside. So, betting on a stock just by looking at the traditional momentum parameters could be risky at times.
It could be safer to invest in bargain stocks that have been witnessing price momentum recently. While the Zacks Momentum Style Score (part of the Zacks Style Scores system), which pays close attention to trends in a stock's price or earnings, is pretty useful in identifying great momentum stocks, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
Krispy Kreme (DNUT - Free Report) is one of the several great candidates that made it through the screen. While there are numerous reasons why this stock is a great choice, here are the most vital ones:
Investors' growing interest in a stock is reflected in its recent price increase. A price change of 8.4% over the past four weeks positions the stock of this doughnut wholesaler and retailer well in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. DNUT meets this criterion too, as the stock gained 22% over the past 12 weeks.
Moreover, the momentum for DNUT is fast paced, as the stock currently has a beta of 1.32. This indicates that the stock moves 32% higher than the market in either direction.
Given this price performance, it is no surprise that DNUT has a Momentum Score of A, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped DNUT earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, DNUT is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. DNUT is currently trading at 0.41 times its sales. In other words, investors need to pay only 41 cents for each dollar of sales.
So, DNUT appears to have plenty of room to run, and that too at a fast pace.
In addition to DNUT, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
Available only May 14-17, get an Orange Dreamsicle Original Glazed® Dozen for just $5 with the purchase of any dozen at regular price
CHARLOTTE, N.C.--(BUSINESS WIRE)--Sunshine just got sweeter. Krispy Kreme® is bringing a splash of summer with a limited-time twist on its iconic Original Glazed® doughnut: Orange Dreamsicle Original Glazed® doughnuts will be available at participating shops only Thursday through Sunday (May 14-17). Inspired by the classic orange-and-cream ice cream treat, this fresh take delivers a smooth vanilla finish wrapped in bright citrus flavor – like summer in every bite.
“Summer flavors have a way of sparking instant happiness,” said Alison Holder, Krispy Kreme Chief Brand and Product Officer. “Our first‑ever Orange Dreamsicle Original Glazed doughnuts are here to deliver that feel‑good flavor now.”
Guests can get an Orange Dreamsicle Original Glazed dozen for just $5 when they purchase any dozen at regular price. The offer is available at participating shops in-shop and drive-thru; limit two per guest. Guests who place an online order for pickup or delivery through Krispy Kreme’s app or website should use promo code ORANGE at checkout; limit one per guest.
Visit www.krispykreme.com/locate/location-search to find a shop near you and share how you're enjoying the new Krispy Kreme Orange Dreamsicle Original Glazed by using #KrispyKreme and tagging @krispykreme on social media. To learn more about this limited-time collection, visit www.krispykreme.com/promos/dreamsicle-doughnuts
About Krispy Kreme
Headquartered in Charlotte, N.C., Krispy Kreme is one of the most beloved and well-known sweet treat brands in the world. Our iconic Original Glazed® doughnut is universally recognized for its hot-off-the-line, melt-in-your-mouth experience. Krispy Kreme operates in more than 40 countries through its unique network of fresh doughnut shops, partnerships with leading retailers, and a rapidly growing digital business. Our purpose of touching and enhancing lives through the joy that is Krispy Kreme guides how we operate every day and is reflected in the love we have for our people, our communities, and the planet. Connect with Krispy Kreme Doughnuts at KrispyKreme.com and follow us on social: X, Instagram and Facebook.
Have you assessed how the international operations of Krispy Kreme (DNUT - Free Report) performed in the quarter ended March 2026? For this doughnut wholesaler and retailer, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.
In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company's reliance on overseas markets has become increasingly crucial, as it offers insights into the company's sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential.
Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors.
Upon examining DNUT's recent quarterly performance, we noticed several interesting patterns in the revenue generated from its international segments, which are commonly analyzed and observed by Wall Street experts.
The company's total revenue for the quarter amounted to $367.03 million, showing decrease of 2.2%. We will now explore the breakdown of DNUT's overseas revenue to assess the impact of its international operations.
Decoding DNUT's International Revenue TrendsMarket Development generated $20.23 million in revenues for the company in the last quarter, constituting 5.5% of the total. This represented a surprise of -3.2% compared to the $20.9 million projected by Wall Street analysts. Comparatively, in the previous quarter, Market Development accounted for $19.69 million (5%), and in the year-ago quarter, it contributed $19.01 million (5.1%) to the total revenue.
International accounted for 34.1% of the company's total revenue during the quarter, translating to $125.26 million. Revenues from this region represented a surprise of +5.72%, with Wall Street analysts collectively expecting $118.48 million. When compared to the preceding quarter and the same quarter in the previous year, International contributed $142.46 million (36.3%) and $119.64 million (31.9%) to the total revenue, respectively.
International Revenue PredictionsIt is projected by analysts on Wall Street that Krispy Kreme will post revenues of $333.42 million for the ongoing fiscal quarter, a decline of 12.2% from the year-ago quarter. The expected contributions from Market Development and International to this revenue are 6.6%, and 36%, translating into $22.03 million, and $120.17 million, respectively.
For the full year, the company is expected to generate $1.31 billion in total revenue, down 14% from the previous year. Revenues from Market Development and International are expected to constitute 7.2% ($94.43 million), and 37.7% ($493.97 million) of the total, respectively.
Concluding RemarksRelying on global markets for revenues presents both prospects and challenges for Krispy Kreme. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.
In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.
Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.
The Zacks Rank, our proprietary stock rating tool, comes with an externally validated impressive track record. It effectively utilizes shifts in earnings projections to act as a dependable barometer for forecasting short-term stock price trends.
At the moment, Krispy Kreme has a Zacks Rank #2 (Buy), signifying that it may outperform the overall market trend in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
A Look at Krispy Kreme's Recent Stock Price PerformanceThe stock has witnessed a decline of 1.2% over the past month versus the Zacks S&P 500 composite's an increase of 8.8%. In the same interval, the Zacks Consumer Staples sector, to which Krispy Kreme belongs, has registered no change. Over the past three months, the company's shares saw an increase of 12.3%, while the S&P 500 increased by 7.1%. In comparison, the sector experienced no change during this timeframe.
CHARLOTTE, N.C.--(BUSINESS WIRE)--You asked. You posted. You tagged. We listened. Krispy Kreme® is officially bringing back the long-time fan-favorite Original Glazed® Lemon Filled Doughnut. And yes, it's as good as you remember. After nonstop love (and not-so-subtle hints) across social media and feedback in our shops, this iconic flavor is making its highly requested comeback starting today (May 18) for a limited time at participating shops nationwide. And if fans show up in a big way, it jus.
CHARLOTTE, N.C.--(BUSINESS WIRE)--He-Man has faced countless villains, and now he's teaming up with Krispy Kreme® to usher in a new era of doughnut deliciousness, defending flavor, fun and epic sweet cravings everywhere. Beginning Tuesday, May 26, at participating shops across the U.S., Krispy Kreme® in collaboration with Mattel and Amazon MGM Studios is unleashing the Masters of the Universe® Collection – three all-new doughnuts available for a limited time and a custom dozen box inspired by M.
Krispy Kreme employees may get more than just free donuts, with a portion of a $1.6 million settlement still up for grabs.
The settlement follows a class action lawsuit filed on behalf of individuals affected by a November 2024 data breach. A cyberattack compromised the personal information—including names, numbers, dates of birth, social security information, and financial accounts—of over 160,000 current and former employees.
The breach was disclosed by Krispy Kreme in December 2024 and a preliminary settlement approval was reached in March. Those affected who wish to submit a claim must do so by June 22 to receive a payment.
Qualifying employees must be residents in the U.S. and must have received a Notice of the Data Incident via email, letting them know their data was compromised during the attack.
Subscribe to the Daily newsletter.Fast Company's trending stories delivered to you every day
“Upon learning of the unauthorized activity, we immediately began taking steps to investigate, contain, and remediate the incident with the assistance of leading cybersecurity experts,” the individual notice said. “In addition to containing the incident, we contacted law enforcement and engaged leading cybersecurity firms to assist us in assessing the incident’s scope and cause.”
Employees were also offered identity monitoring services like credit monitoring, fraud consultation, and identity theft restoration, the notice said.
Those who believe they have been affected but did not receive a notice should contact the settlement administrators. Eligible class members may accept a single payment of $75 or go the extra mile by submitting an itemized claim form for up to $3,500. Individuals may file by mail or online via the settlement’s website. The itemized claim must provide proof like receipts, emails or phone records.
Persons affected by the security breach who wish to reserve their right to sue in the future may opt out of the settlement if they do so before June 6.
The final deadline for Fast Company's Next Big Things in Tech Awards is Friday, June 12, at 11:59 p.m. PT. Apply today.
ABOUT THE AUTHOR
María José Gutierrez Chavez is a trending news writer for Fast Company. She was previously the editorial fellow at Inc More
CHARLOTTE, N.C.--(BUSINESS WIRE)--The countdown is on to National Doughnut Day – and there's one destination that does it best: Krispy Kreme®. This Friday (June 5), Krispy Kreme is celebrating the sweetest day of the year by treating guests to a free doughnut of their choice – no purchase necessary.* It's simple: stop by, pick your favorite and enjoy. From the iconic Original Glazed® to classics like Strawberry Iced with Sprinkles or Chocolate Iced Kreme™ Filled, Krispy Kreme is serving up the.
It’s the first Friday of June (June 5, 2026), and that means it is once again National Donut Day in America (or National Doughnut Day, if you’re Krispy Kreme).
Despite the urge to assume the unofficial holiday is just another modern-day marketing scheme by the donut industrial complex, National Donut Day’s origin actually goes back nearly 90 years.
As Fast Company previously reported, the first National Donut Day was actually observed in 1938. Per SFGate, the Salvation Army declared the holiday that year to commemorate the volunteers who handed out donuts to frontline soldiers during World War I.
Those volunteers, all women, became known as “doughgirls.”
Subscribe to the Daily newsletter.Fast Company's trending stories delivered to you every day
Of course, today the patriotic aspects of National Donut Day have largely been forgotten, and the 21st-century donut giants now use the day as a way to reward loyal customers with deals and freebies—and to entice them into their shops to buy even more donuts.
Here are how three of the largest donut sellers in America are celebrating National Donut Day.
Krispy KremeThe national donut chain that has never failed to find a reason to give away free donuts is, of course, giving away free donuts on National Donut Day, or, as Krispy Kreme calls it, National Doughnut Day.
Krispy Kreme remains a hold as turnaround progress is evident, but valuation uncertainty persists. Q1 marked the first positive free cash flow since IPO, with adjusted EBITDA up 38% YoY and 260 bps margin expansion. FY 2026 guidance targets $1.25–$1.35B net revenue, $140–$150M adjusted EBITDA, and over $15M free cash flow.
CHARLOTTE, N.C.--(BUSINESS WIRE)--The world's biggest soccer moments deserve an equally sweet celebration, and Krispy Kreme® is bringing the flavor with its all-new Match Day Dozen. Available for a limited time from Thursday through Sunday (June 11-14) at participating Krispy Kreme shops across the U.S., the Match Day Dozen is the ultimate game-day treat. Whether you're cheering from the couch, gathering with friends, rocking your lucky jersey, or celebrating every goal, save, and nail-biting f.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the first quarter 2026 after market close on Wednesday, May 6, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 461-5787 for U.S. participants and +1 (585) 542-9983 for international participants and referenc.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of agilon health, inc. (NYSE: AGL) breached their fiduciary duties to shareholders.
If you currently own agilon stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
Agilon Health (NYSE:AGL – Get Free Report) and iSpecimen (NASDAQ:ISPC – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.
Risk and Volatility Agilon Health has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, iSpecimen has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.
Earnings & Valuation This table compares Agilon Health and iSpecimen”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agilon Health $5.93 billion 0.06 -$391.35 million ($23.75) -0.95 iSpecimen $1.93 million 1.68 -$10.49 million ($2.35) -0.05 iSpecimen has lower revenue, but higher earnings than Agilon Health. Agilon Health is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership 13.6% of iSpecimen shares are owned by institutional investors. 2.3% of Agilon Health shares are owned by insiders. Comparatively, 12.2% of iSpecimen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations This is a breakdown of current recommendations and price targets for Agilon Health and iSpecimen, as reported by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agilon Health 2 10 3 0 2.07 iSpecimen 1 0 0 0 1.00 Agilon Health currently has a consensus price target of $40.23, indicating a potential upside of 77.91%. Given Agilon Health’s stronger consensus rating and higher possible upside, research analysts clearly believe Agilon Health is more favorable than iSpecimen.
Profitability This table compares Agilon Health and iSpecimen’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Agilon Health -6.60% -120.82% -24.89% iSpecimen -543.37% -496.31% -133.56% About Agilon Health (Get Free Report)
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.
About iSpecimen (Get Free Report)
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Agilon Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilon Health and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEJ-Long Group (NASDAQ:JL) and Crocs (NASDAQ:CROX) Financial Survey
NEXT HEADLINE »Financial Survey: Saratoga Investment (NYSE:SAR) versus Gladstone Investment (NASDAQ:GAIN)
agilon health is rated a cautious 'Hold' as management executes a strategic downsizing to address persistent losses. Recent exits from underperforming markets and partnerships are expected to improve medical margin from -$56.6 million in 2025 to $325 million in 2026. Despite revenue and membership declines, AGL guides for near break-even EBITDA in 2026, a significant improvement from -$296.2 million prior.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Agilon Health (AGL - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Agilon Health is one of 891 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AGL's full-year earnings has moved 40.2% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AGL has returned about 64.4% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 5.5% on average. This shows that Agilon Health is outperforming its peers so far this year.
Another stock in the Medical sector, Caribou Biosciences, Inc. (CRBU - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 44%.
For Caribou Biosciences, Inc., the consensus EPS estimate for the current year has increased 9.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Agilon Health belongs to the Medical Services industry, a group that includes 62 individual companies and currently sits at #87 in the Zacks Industry Rank. This group has lost an average of 9.5% so far this year, so AGL is performing better in this area.
Caribou Biosciences, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 436-stock industry is ranked #92. The industry has moved +2.5% so far this year.
Agilon Health and Caribou Biosciences, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health (NYSE: AGL) (the “Company”), the trusted partner empowering physicians to transform health care in our communities, today announced the appointment of Tim O'Rourke as Chief Executive Officer and a member of the Company's Board of Directors, effective May 7. He succeeds Ronald A. Williams, who has served as Executive Chairman since August 2025 and will continue as Chairman of the Board. The appointment comes as agilon enters a new phase following.
An AGL Energy logo is visible above their offices in Adelaide, Australia, September 18, 2025. REUTERS/Hollie Adams. Purchase Licensing Rights, opens new tab
SummaryCompaniesCompany lifts its fiscal 2026 operating earnings forecastSees pressure from softer market conditions in FY27Sees Liddell battery fully operational by year-endMay 6 (Reuters) - Australia's AGL Energy (AGL.AX), opens new tab raised the lower end of its annual profit forecast range on Wednesday, banking on better plant performance and tighter cost control, and said it is well placed for the next three months during the global fuel crisis.
Australia's top power producer now expects 2026 underlying net profit after tax between A$610 million and A$680 million ($437.98 million and $488.24 million), compared with the A$580 million to A$680 million previously expected and a Visible Alpha consensus of A$646.3 million.
The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.
It also raised its annual operating earnings forecast to between A$2.06 billion and A$2.18 billion, compared with the A$2.02 billion to A$2.18 billion previously expected and the Visible Alpha estimate of A$2.14 billion.
AGL shares rose 0.42% on Wednesday while the S&P/ASX200 (.AXJO), opens new tab was up 1.3%.
Amid diesel supply disruptions in Australia triggered by the Middle East conflict, Chief Executive Damien Nicks said AGL was well placed with fuel supplies and its Bayswater power station had 90 days worth of diesel on hand.
The plant uses diesel in start-up and shutdown processes for its coal-fired units and for heavy machinery and trucks.
"We're very comfortable with the supplies we have. We can continue to get access to diesel," he told the Macquarie Australia Conference in Sydney.
"We believe we'll continue to get it as an essential services provider."
AGL attributed the upgraded forecast to improved plant availability and flexibility, a good showing by its thermal generation fleet, improved customer markets performance and disciplined cost management.
While the broader sector faces headwinds from elevated fuel costs and geopolitical risks, the upgrade highlights that well-run operators with diversified assets and strong cost control can still navigate this environment successfully, said Tim Waterer, chief market analyst at KCM Trade.
"It's an encouraging sign for the Australian energy sector," Waterer said.
AGL, Australia's largest corporate carbon emitter, had said in February that it was targeting A$50 million in sustainable net operating cost reductions in FY27.
The company on Wednesday warned of pressure from softer domestic and global market conditions in fiscal 2027, along with declining wholesale prices in select locations.
AGL will take into account these factors in its 2027 forecast, to be presented at its annual results in August, together with the full-year contribution from its Liddell Battery project and cost-saving measures.
The project, a 500-MW grid-scale battery in New South Wales, is expected to be fully operational by June.
($1 = 1.3928 Australian dollars)
Reporting by Scott Murdoch in Sydney, Sneha Kumar in Bengaluru, additional reporting by Roshan Thomas; Editing by Jonathan Ananda and Subhranshu Sahu
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Scott Murdoch has been a journalist for more than two decades working for Thomson Reuters and News Corp in Australia. He has specialised in financial journalism for most of his career and covers the Australian financial services sector and superannuation. He is based in Sydney.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the first quarter ended March 31, 2026. In addition, the company increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. “Our strong first-quarter performance and increase in full-year 2026 guidance reflects disciplined execution and progress against our strategic priorities. We.
Agilon Health (AGL - Free Report) reported $1.42 billion in revenue for the quarter ended March 2026, representing a year-over-year decline of 7.3%. EPS of $1.80 for the same period compares to $0 a year ago.
The reported revenue represents a surprise of +3.28% over the Zacks Consensus Estimate of $1.38 billion. With the consensus EPS estimate being $1.13, the EPS surprise was +58.73%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Agilon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Avg. Medicare Advantage Members: 424,000 versus 473,750 estimated by two analysts on average.Revenues- Medical services: $1.42 billion versus the three-analyst average estimate of $1.37 billion. The reported number represents a year-over-year change of -7.3%.Revenues- Other operating: $1.91 million compared to the $2.83 million average estimate based on three analysts. The reported number represents a change of -34.2% year over year.View all Key Company Metrics for Agilon here>>>
Shares of Agilon have returned +61.2% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Agilon Health (AGL - Free Report) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +58.73%. A quarter ago, it was expected that this senior-focused health care company would post a loss of $6.75 per share when it actually produced a loss of $11.5, delivering a surprise of -70.37%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Agilon, which belongs to the Zacks Medical Services industry, posted revenues of $1.42 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.28%. This compares to year-ago revenues of $1.53 billion. The company has topped consensus revenue estimates three times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Agilon shares have added about 55.3% since the beginning of the year versus the S&P 500's gain of 6%.
What's Next for Agilon?While Agilon has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Agilon was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$1.44 on $1.33 billion in revenues for the coming quarter and -$6.36 on $5.45 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Ascend Wellness Holdings, Inc. (AAWH - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 13.
This company is expected to post quarterly loss of $0.13 per share in its upcoming report, which represents a year-over-year change of -44.4%. The consensus EPS estimate for the quarter has been revised 3.9% higher over the last 30 days to the current level.
Ascend Wellness Holdings, Inc.'s revenues are expected to be $114.2 million, down 10.8% from the year-ago quarter.
Agilon Health Inc. (NYSE:AGL) shares are soaring on Thursday as the company recently announced an increase in its full-year 2026 guidance. The company operates and manages a network of independent physicians.
Agilon Health Shares Rise After Guidance IncreaseThe company announced results that reflect disciplined execution and progress against its strategic priorities.
Agilon Health reported first-quarter earnings of $1.80 per share, beating the consensus of $1.31.
Sales reached $1.42 billion, surpassing the Wall Street estimate of $1.38 billion.
Revenues fell 7% year over year, reflecting lower year-over-year membership partially offset by improved pricing, contract economics, and burden of illness performance.
Membership Declines While Margins ImproveTotal members on the Agilon platform decreased to 536,000 as of March 31, 2026, including 426,000 Medicare Advantage members and 110,000 ACO model beneficiaries.
Medical margin was $149 million, up from $128 million a year ago. Medical margin includes the cost trend for Medicare Advantage members reserved at 7.4%.
Adjusted EBITDA was $54 million, up from $21 million a year ago.
We are seeing early returns from investments in data and technology, clinical execution, and operating discipline,” said Ronald Williams, Executive Chairman.
Agilon Health Raises 2026 Revenue Outlook“We are also strengthening our Total Care Model—expanding clinical pathways, improving quality, and deepening payor alignment—positioning us for more predictable outcomes and sustained margin expansion. We remain confident in our 2026 outlook and long-term growth trajectory,” Williams further added.
Agilon Health expects second-quarter sales of $1.44 billion-$1.48 billion compared to the consensus of $1.34 billion.
The company raised its fiscal 2026 sales guidance from $5.41 billion-$5.58 billion to $5.68 billion-$5.81 billion, versus the consensus of $5.45 billion.
William Blair notes it was a good start to 2026, and ongoing clinical, cost-cutting, and operational initiatives appear to be driving a solid turnaround at the company.
How Agilon Health (AGL) Ranks On MomentumBelow is the Benzinga Edge scorecard for Agilon Health, highlighting its strengths and weaknesses compared to the broader market:
Momentum: Neutral (Score: 58.56) — Stock is showing moderate performance indicators. The Verdict: Agilon Health’s Benzinga Edge signal reveals a momentum-driven story, suggesting that while the stock has shown some recovery, it remains to be seen if this upward trend can be sustained in the long term.
AGL Price Action: Agilon Health shares were up 99.89% at $55.67 at the time of publication on Thursday, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
Agilon Health shares rose sharply after the healthcare company posted better-than-expected first-quarter results and boosted its full-year guidance. (Dreamstime)
Shares of Agilon Health headed for their best day on record after the beleaguered healthcare company posted better-than-expected earnings, coupled with an outpouring of glowing commentary from analysts.
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase, investors find themselves invested in shares that have limited to no upside or even a downside. So, betting on a stock just by looking at the traditional momentum parameters could be risky at times.
A safer approach could be investing in bargain stocks with recent price momentum. While the Zacks Momentum Style Score (part of the Zacks Style Scores system) helps identify great momentum stocks by paying close attention to trends in a stock's price or earnings, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
There are several stocks that currently pass through the screen and Agilon Health (AGL - Free Report) is one of them. Here are the key reasons why this stock is a great candidate.
A dash of recent price momentum reflects growing interest of investors in a stock. With a four-week price change of 185.1%, the stock of this senior-focused health care company is certainly well-positioned in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. AGL meets this criterion too, as the stock gained 500.9% over the past 12 weeks.
Moreover, the momentum for AGL is fast paced, as the stock currently has a beta of 2.29. This indicates that the stock moves 129% higher than the market in either direction.
Given this price performance, it is no surprise that AGL has a Momentum Score of A, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped AGL earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, AGL is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. AGL is currently trading at 0.16 times its sales. In other words, investors need to pay only 16 cents for each dollar of sales.
So, AGL appears to have plenty of room to run, and that too at a fast pace.
In addition to AGL, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Agilon Health (AGL - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agilon Health is one of 888 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AGL's full-year earnings has moved 47.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AGL has returned about 215% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -8.2% on a year-to-date basis. This shows that Agilon Health is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Amarin (AMRN - Free Report) . The stock is up 7.9% year-to-date.
The consensus estimate for Amarin's current year EPS has increased 12.1% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Agilon Health belongs to the Medical Services industry, a group that includes 63 individual companies and currently sits at #98 in the Zacks Industry Rank. Stocks in this group have lost about 11% so far this year, so AGL is performing better this group in terms of year-to-date returns.
In contrast, Amarin falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 432 stocks and is ranked #142. Since the beginning of the year, the industry has moved -1.8%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Agilon Health and Amarin as they could maintain their solid performance.
Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."
Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase, investors find themselves invested in shares that have limited to no upside or even a downside. So, betting on a stock just by looking at the traditional momentum parameters could be risky at times.
A safer approach could be investing in bargain stocks with recent price momentum. While the Zacks Momentum Style Score (part of the Zacks Style Scores system) helps identify great momentum stocks by paying close attention to trends in a stock's price or earnings, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
There are several stocks that currently pass through the screen and Agilon Health (AGL - Free Report) is one of them. Here are the key reasons why this stock is a great candidate.
A dash of recent price momentum reflects growing interest of investors in a stock. With a four-week price change of 205.6%, the stock of this senior-focused health care company is certainly well-positioned in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. AGL meets this criterion too, as the stock gained 501.1% over the past 12 weeks.
Moreover, the momentum for AGL is fast paced, as the stock currently has a beta of 2.29. This indicates that the stock moves 129% higher than the market in either direction.
Given this price performance, it is no surprise that AGL has a Momentum Score of A, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped AGL earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Most importantly, despite possessing fast-paced momentum features, AGL is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. AGL is currently trading at 0.24 times its sales. In other words, investors need to pay only 24 cents for each dollar of sales.
So, AGL appears to have plenty of room to run, and that too at a fast pace.
In addition to AGL, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Agilon Health (AGL - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Agilon Health is a member of the Medical sector. This group includes 884 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AGL's full-year earnings has moved 62.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, AGL has gained about 395.3% so far this year. Meanwhile, stocks in the Medical group have lost about 6% on average. This means that Agilon Health is outperforming the sector as a whole this year.
Another stock in the Medical sector, Humacyte, Inc. (HUMA - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 15.6%.
In Humacyte, Inc.'s case, the consensus EPS estimate for the current year increased 28% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Agilon Health is a member of the Medical Services industry, which includes 62 individual companies and currently sits at #87 in the Zacks Industry Rank. This group has lost an average of 11.6% so far this year, so AGL is performing better in this area.
Humacyte, Inc., however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 430-stock industry is ranked #142. The industry has moved -0.5% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Agilon Health and Humacyte, Inc. as they attempt to continue their solid performance.
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Agilon Health (AGL - Free Report) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Agilon Health currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for AGL that show why this senior-focused health care company shows promise as a solid momentum pick.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For AGL, shares are up 5.7% over the past week while the Zacks Medical Services industry is up 0.93% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 223.52% compares favorably with the industry's 1.25% performance as well.
Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Shares of Agilon Health have increased 416.71% over the past quarter, and have gained 53.58% in the last year. In comparison, the S&P 500 has only moved 9.66% and 28.33%, respectively.
Investors should also take note of AGL's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now AGL is averaging 581,877 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with AGL.
Over the past two months, 3 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost AGL's consensus estimate, increasing from -$6.38 to -$3.78 in the past 60 days. Looking at the next fiscal year, 4 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineTaking into account all of these elements, it should come as no surprise that AGL is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Agilon Health on your short list.
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that members of its management team will participate in investor meetings and industry discussions at the following conferences:
Truist Securities Healthcare Disruptors & Digital Health Conference on Tuesday, June 23, 2026 in New York. Management will participate in an ACO Model panel discussion at 1:50pm ET and conduct one-on-one meetings with investors. Citizens Healthcare Services Forum on Thursday, June 25, 2026 in Boston. Management will conduct one-on-one meetings with investors. Due to the format of these events, meetings will not be available for webcasting. Interested investors and other parties may contact the conference organizers or agilon health’s Investor Relations team for registration information.
About agilon health
agilon health is the trusted partner empowering physicians to transform health care in our communities. Through our partnerships and purpose-built platform, agilon is accelerating at scale how physician groups and health systems transition to a value-based Total Care Model for their senior patients. agilon provides the technology, people, capital, process, and access to a peer network of approximately 2,200 primary care physicians (PCPs) that allow its physician partners to maintain their independence and focus on the total health of their most vulnerable patients. Together, agilon and its physician partners are creating the healthcare system we need – one built on the value of care, not the volume of fees. The result: healthier communities and empowered doctors. agilon is the trusted partner in approximately 30 diverse communities and is here to help more of our nation's leading physician groups and health systems have a sustained, thriving future. For more information visit www.agilonhealth.com and connect with us on LinkedIn.
Executives from Casella Waste Systems (NASDAQ: CWST) outlined near-term leadership priorities, cost initiatives, acquisition plans, and landfill capacity developments during a Q&A session at a J.P. Morgan conference. CEO priorities center on safety, culture, and organizational alignment Chief Executive Officer Ned Coletta, who said he has been with the company for 21 years and previously served
March 25, 2026 16:05 ET | Source: Casella Waste Systems, Inc.
RUTLAND, Vt., March 25, 2026 (GLOBE NEWSWIRE) -- Casella Waste Systems, Inc. (Nasdaq: CWST), a regional solid waste, recycling, and resource management services company, announced today that the company’s management will be participating at the following investor conference:
Gabelli Funds 12th Annual Waste and Sustainability Symposium
Thursday, April 9, 2026 A copy of the presentation material will be available before the Company presents and may be accessed in the “Events & Presentations” section of the company’s investor website at http://ir.casella.com. Where applicable, a live webcast link will be posted on the company’s investor website.
For further information, contact Jason Mead, Senior Vice President of Finance and Treasurer at (802) 772-2293, or visit the company’s website at http://www.casella.com.
Shares of Casella Waste Systems, Inc. (NASDAQ: CWST - Get Free Report) reached a new 52-week low on Thursday. The company traded as low as $74.05 and last traded at $76.43, with a volume of 813726 shares. The stock had previously closed at $76.06. Analyst Upgrades and Downgrades Several equities analysts recently issued reports on
April 01, 2026 16:01 ET | Source: Casella Waste Systems, Inc.
RUTLAND, Vt., April 01, 2026 (GLOBE NEWSWIRE) -- Casella Waste Systems, Inc. (Nasdaq: CWST), a regional solid waste, recycling, and resource management services company (the “Company”), today announced that it has completed the acquisition of Star Waste Systems, LLC (“Star Waste”), a privately held waste collection company with operations in eastern Massachusetts, including the greater Boston area, and southern New Hampshire.
The transaction closed on April 1, 2026, and is expected to generate approximately $100 million of annualized revenue. The acquisition was funded through cash on hand and available capacity under the Company’s revolving credit facility.
Star Waste provides residential, commercial, and roll-off collection services to approximately 80,000 locations across its operating footprint. The acquired business includes three solid waste collection locations and a construction and demolition (C&D) processing and transfer station.
“We are excited to welcome the Star Waste team to Casella,” said Edmond R. “Ned” Coletta, President and Chief Executive Officer. “This acquisition strategically augments our asset positioning and enhances our collection density in the highly attractive Boston market. We look forward to working with Star Waste’s employees to further build on their strong reputation for exceptional customer service.”
“With the acquisition of Star Waste, we have acquired four businesses year-to-date, with total annualized revenues of approximately $150 million. This is a strong start to 2026, and positions us well for continued growth and strategic execution.”
About Casella Waste Systems, Inc.
Casella Waste Systems, Inc., headquartered in Rutland, Vermont, provides resource management expertise and services to residential, commercial, municipal, institutional and industrial customers, primarily in the areas of solid waste collection and disposal, transfer, recycling and organics services in the eastern United States. For further information, investors may visit the Company’s website at https://www.casella.com.
Safe Harbor Statement
Certain matters discussed in this press release, including but not limited to, the statements regarding our intentions, beliefs or current expectations concerning, among other things, projections as to the anticipated benefits of this acquisition; and the anticipated impact of this acquisition on the Company’s business and future financial and operating results are "forward-looking statements". These forward-looking statements can generally be identified as such by the context of the statements, including words such as “believe,” “expect,” “anticipate,” “plan,” “may,” “would,” “intend,” “estimate,” “will,” “guidance” and other similar expressions, whether in the negative or affirmative. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates and management’s beliefs and assumptions. The Company cannot guarantee that it will achieve the financial results, plans, intentions, expectations or guidance disclosed in the forward-looking statements made. Such forward-looking statements, and all phases of the Company’s operations, involve a number of risks and uncertainties, any one or more of which could cause actual results to differ materially from those described in its forward-looking statements.
Such risks and uncertainties include or relate to, among other things, the following: Company may not fully recognize the expected strategic and financial benefits from the acquisition due to an inability to recognize operational cost savings, market factors, or competitive, economic or other factors outside its control which may impact revenue and costs.
There are a number of other important risks and uncertainties that could cause the Company's actual results to differ materially from those indicated by such forward-looking statements. These additional risks and uncertainties include, without limitation, those detailed in Item 1A, “Risk Factors” in the Company's Form 10-K for the fiscal year ended December 31, 2025, and in other filings that the Company may make with the Securities and Exchange Commission in the future.
The Company undertakes no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investors:
Jason Mead
Senior Vice President of Finance & Treasurer
(802) 772-2293
Media:
Jeff Weld
Vice President of Communications
(802) 772-2234
http://www.casella.com
SG Americas Securities LLC increased its holdings in Casella Waste Systems, Inc. (NASDAQ:CWST – Free Report) by 103.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,268 shares of the industrial products company’s stock after purchasing an additional 12,334 shares during the quarter. SG Americas Securities LLC’s holdings in Casella Waste Systems were worth $2,377,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in CWST. Smartleaf Asset Management LLC grew its position in Casella Waste Systems by 180.2% in the third quarter. Smartleaf Asset Management LLC now owns 297 shares of the industrial products company’s stock worth $27,000 after buying an additional 191 shares during the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of Casella Waste Systems by 301.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 245 shares of the industrial products company’s stock worth $27,000 after acquiring an additional 184 shares in the last quarter. First Horizon Corp acquired a new position in shares of Casella Waste Systems in the 3rd quarter worth $31,000. EverSource Wealth Advisors LLC raised its position in shares of Casella Waste Systems by 235.3% during the second quarter. EverSource Wealth Advisors LLC now owns 285 shares of the industrial products company’s stock worth $33,000 after purchasing an additional 200 shares during the period. Finally, Optiver Holding B.V. lifted its holdings in shares of Casella Waste Systems by 280.0% during the third quarter. Optiver Holding B.V. now owns 399 shares of the industrial products company’s stock valued at $38,000 after purchasing an additional 294 shares during the last quarter. 99.51% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth A number of equities analysts recently weighed in on the company. Zacks Research upgraded Casella Waste Systems from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Raymond James Financial reiterated a “strong-buy” rating and issued a $115.00 target price on shares of Casella Waste Systems in a report on Monday, February 23rd. Barclays boosted their price target on shares of Casella Waste Systems from $95.00 to $101.00 and gave the company an “equal weight” rating in a report on Monday, February 23rd. Weiss Ratings lowered shares of Casella Waste Systems from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, February 23rd. Finally, Jefferies Financial Group set a $120.00 target price on shares of Casella Waste Systems and gave the company a “buy” rating in a research note on Tuesday, January 6th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $113.11.
Check Out Our Latest Analysis on CWST
Insider Activity at Casella Waste Systems In other news, CAO Kevin Drohan sold 675 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $92.61, for a total value of $62,511.75. Following the transaction, the chief accounting officer directly owned 7,462 shares of the company’s stock, valued at approximately $691,055.82. This represents a 8.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Bradford John Helgeson sold 405 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $87.73, for a total value of $35,530.65. Following the sale, the chief financial officer owned 7,342 shares of the company’s stock, valued at approximately $644,113.66. This represents a 5.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 15,830 shares of company stock valued at $1,454,208. Insiders own 3.81% of the company’s stock.
Casella Waste Systems Price Performance Shares of CWST opened at $87.18 on Friday. The business’s 50-day moving average is $93.34 and its 200-day moving average is $94.00. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.26 and a quick ratio of 1.26. The company has a market capitalization of $5.54 billion, a price-to-earnings ratio of 726.56 and a beta of 0.84. Casella Waste Systems, Inc. has a fifty-two week low of $74.05 and a fifty-two week high of $121.24.
Casella Waste Systems (NASDAQ:CWST – Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The industrial products company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.08. The firm had revenue of $469.06 million for the quarter, compared to the consensus estimate of $471.32 million. Casella Waste Systems had a net margin of 0.43% and a return on equity of 5.17%. The firm’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.41 earnings per share. Equities research analysts expect that Casella Waste Systems, Inc. will post 1.16 EPS for the current fiscal year.
Casella Waste Systems Profile (Free Report)
Casella Waste Systems, Inc is a regional resource management company headquartered in Rutland, Vermont. Established in 1975, the company has grown from a single-truck operation into a multi-state provider of integrated waste management solutions. Casella offers a comprehensive range of services, including residential, commercial and industrial waste collection, transfer station operations, landfill disposal, recycling processing and organics management.
Through a network of solid waste transfer stations, recycling facilities and landfills, Casella serves communities primarily across the northeastern United States and parts of the mid-Atlantic region.
Further Reading Five stocks we like better than Casella Waste Systems
Receive News & Ratings for Casella Waste Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Casella Waste Systems and related companies with MarketBeat.com's FREE daily email newsletter.
April 07, 2026 16:01 ET | Source: Casella Waste Systems, Inc.
RUTLAND, Vt., April 07, 2026 (GLOBE NEWSWIRE) -- Casella Waste Systems, Inc. (Nasdaq: CWST), a regional solid waste, recycling, and resource management services company, will release its financial results for the three months ended March 31, 2026, after the market closes on Thursday, April 30, 2026.
The company will host a conference call to discuss these results on Friday, May 1, 2026, at 10:00 a.m. Eastern Time. Individuals interested in participating in the call should register by clicking here to obtain dial in and passcode details.
The call will also be webcast; to listen, participants should visit the company’s website at http://ir.casella.com and follow the appropriate link to the webcast. A replay of the call will be available on the company’s website and accessible using the same link.
For further information, contact Jason Mead, Senior Vice President of Finance and Treasurer, at (802) 772-2293 or visit the company’s website at http://www.casella.com.
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Casella (CWST - Free Report) , which belongs to the Zacks Waste Removal Services industry, could be a great candidate to consider.
This provider of garbage-disposal and recycling services has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 29.95%.
For the last reported quarter, Casella came out with earnings of $0.3 per share versus the Zacks Consensus Estimate of $0.22 per share, representing a surprise of 36.36%. For the previous quarter, the company was expected to post earnings of $0.34 per share and it actually produced earnings of $0.42 per share, delivering a surprise of 23.53%.
Price and EPS Surprise
With this earnings history in mind, recent estimates have been moving higher for Casella. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Casella currently has an Earnings ESP of +103.40%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on April 30, 2026.
Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.
Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.
Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
The market expects Casella (CWST - Free Report) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.
The earnings report, which is expected to be released on April 30, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus EstimateThis provider of garbage-disposal and recycling services is expected to post quarterly earnings of $0.10 per share in its upcoming report, which represents a year-over-year change of -47.4%.
Revenues are expected to be $457.62 million, up 9.7% from the year-ago quarter.
Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 8.93% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Price, Consensus and EPS Surprise
Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Casella?For Casella, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +15.48%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination indicates that Casella will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Casella would post earnings of $0.22 per share when it actually produced earnings of $0.30, delivering a surprise of +36.36%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Casella appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Expected Results of an Industry PlayerAnother stock from the Zacks Waste Removal Services industry, Xylem (XYL - Free Report) , is soon expected to post earnings of $1.09 per share for the quarter ended March 2026. This estimate indicates a year-over-year change of +5.8%. Revenues for the quarter are expected to be $2.11 billion, up 1.8% from the year-ago quarter.
Over the last 30 days, the consensus EPS estimate for Xylem has been revised 0.3% down to the current level. Nevertheless, the company now has an Earnings ESP of +0.86%, reflecting a higher Most Accurate Estimate.
When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Xylem will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
